GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » CVRx Inc (NAS:CVRX) » Definitions » Interest Coverage

CVRx (CVRX) Interest Coverage : 0 (At Loss) (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is CVRx Interest Coverage?

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. CVRx's Operating Income for the three months ended in Mar. 2024 was $-22.23 Mil. CVRx's Interest Expense for the three months ended in Mar. 2024 was $-0.96 Mil. did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is.

The historical rank and industry rank for CVRx's Interest Coverage or its related term are showing as below:


CVRX's Interest Coverage is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 18.18
* Ranked among companies with meaningful Interest Coverage only.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.


CVRx Interest Coverage Historical Data

The historical data trend for CVRx's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

CVRx Interest Coverage Chart

CVRx Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Interest Coverage
- - - - -

CVRx Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Interest Coverage Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of CVRx's Interest Coverage

For the Medical Devices subindustry, CVRx's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CVRx's Interest Coverage Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, CVRx's Interest Coverage distribution charts can be found below:

* The bar in red indicates where CVRx's Interest Coverage falls into.



CVRx Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage=-1* Operating Income /Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt (1).


Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

CVRx's Interest Coverage for the fiscal year that ended in Dec. 2023 is calculated as

Here, for the fiscal year that ended in Dec. 2023, CVRx's Interest Expense was $-1.80 Mil. Its Operating Income was $-43.10 Mil. And its Long-Term Debt & Capital Lease Obligation was $30.38 Mil.

CVRx did not have earnings to cover the interest expense.

CVRx's Interest Coverage for the quarter that ended in Mar. 2024 is calculated as

Here, for the three months ended in Mar. 2024, CVRx's Interest Expense was $-0.96 Mil. Its Operating Income was $-22.23 Mil. And its Long-Term Debt & Capital Lease Obligation was $30.36 Mil.

CVRx did not have earnings to cover the interest expense.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's Financial Strength is.


CVRx  (NAS:CVRX) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .


CVRx Interest Coverage Related Terms

Thank you for viewing the detailed overview of CVRx's Interest Coverage provided by GuruFocus.com. Please click on the following links to see related term pages.


CVRx (CVRX) Business Description

Traded in Other Exchanges
N/A
Address
9201 West Broadway Avenue, Suite 650, Minneapolis, MN, USA, 55445
CVRx Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its proprietary platform technology, Barostim, is designed to leverage the power of the brain to address the imbalance of the Autonomic Nervous System, which causes heart failure and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy which in turn triggers an autonomic response to the heart. The majority of revenue is derived from the USA market.
Executives
Johnson & Johnson Innovation - Jjdc, Inc. 10 percent owner 410 GEORGE STREET, NEW BRUNSWICK NJ 08901
Paul Verrastro officer: Chief Marketing Officer 9201 W BROADWAY AVE, #650, MINNEAPOLIS MN 55445
Kevin Hykes director 2 GOODYEAR, SUITE B, IRVINE CA 92618
Kirk G. Nielsen director ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Mudit K. Jain director C/O TREO VENTURES, 140 WASHINGTON STREET, SUITE 200, RENO NV 89503
Craig E. Palmer officer: SVP, U.S. Sales 9201 WEST BROADWAY AVENUE, SUITE 650, MINNEAPOLIS MN 55445
Martha Shadan director 9201 W BROADWAY AVE, #650, MINNEAPOLIS MN 55445
New Enterprise Associates 10 L P 10 percent owner
Nea Partners 10 L P 10 percent owner 1119 ST PAUL STREET, BALTIMORE MD 21202
Geoffrey B Pardo director 100 DOMAIN DRIVE, EXETER NH 03833
Jared Oasheim officer: Chief Financial Officer 9201 W BROADWAY AVE, #650, MINNEAPOLIS MN 55445
John Brintnall officer: Chief Strategy Officer and Sec 9201 W BROADWAY AVE, #650, MINNEAPOLIS MN 55445
Dean Bruhn-ding officer: VP of Reg. Affairs and QA 9201 W BROADWAY AVE, #650, MINNEAPOLIS MN 55445
Liz Galle officer: VP of Global Clinical Research 9201 W BROADWAY AVE, #650, MINNEAPOLIS MN 55445
Nadim Yared director, officer: Chief Executive Officer 9201 W BROADWAY AVE #650, MINNEAPOLIS MN 55445